Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2011

View Archived Issues

Takeda presents clinical and preclinical data on TAK-875 in diabetes

Second pivotal phase III Quad study meets primary endpoint

FDA grants priority review to BTG's BLA for experimental methotrexate toxicity treatment

First patient dosed in phase I trial of Marshall Edwards' lead anticancer drug

GWAS identifies new loci linked to susceptibility to Alzheimer's disease

New osteoporosis therapy prevents bone loss by directing mesenchymal stem cells to bone

Orchid Chemicals & Pharmaceuticals discloses new antibacterial oxazolidinone

New broad-spectrum antibacterial compound presented

New brain-penetrant MAPK 10 inhibitor presented as therapeutic candidate for Huntington's disease

Topline phase III data on budesonide MMX to be used to support NDA submission

Novartis launches Onbrez inhalation capsules in Japan

First part of phase I SPI-1620 trial provides encouraging data

SanBio opens phase I/IIa study of neural regenerating cells

FerroKin chelator enters phase II trial in transfusion-dependent pediatric patients with anemia

Novel Mnk inhibitors synthesized at Boehringer Ingelheim Pharma

Novo Nordisk claims new melanocortin receptor modulators

Japan Tobacco presents novel HIV integrase inhibitors

Jazz Pharmaceuticals and Azur Pharma agree to merge

Mitsubishi Tanabe Pharma patents new phosphodiesterase 10A inhibitors

Niiki Pharma reports promising interim phase I data on NKP-1339

Progen to close phase Ia study of PG-545

Bionomics provides update on BNC-105 study in metastatic renal cell carcinoma

PX-102 enters clinical development

European approval of Removab broadened

Sanofi Pasteur and UC San Diego to collaborate on immunological approach to acne

Japanese company discloses novel fatty-acid amide hydrolase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...